BioSpace News Archive

SI-BONE, Inc., a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced the worldwide launch of the SI-BONE SImulator™.

Panbela Therapeutics, Inc., a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, announced the closing of its previously announced public offering of 3,333,334 shares of common stock of the Company at a price to the public of $3.00 per share, less underwriting discounts and commissions.

Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan in accordance with NYSE American Company Guide Section 711.

SOPHiA GENETICS SA, the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 80,400 shares of G1’s common stock to eight employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

Ocugen, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, announced that its co-development partner, Bharat Biotech, shared positive results of its Phase 3 study of COVAXIN™, a whole virion inactivated COVID-19 vaccine candidate.

Solid Biosciences Inc., a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced the grant of an inducement award to its newly appointed Senior Vice President, Clinical Development, Roxana Dreghici.

Debbie’s Dream Foundation: Curing Stomach Cancer and the Korean Cancer Association hosted a record high 935 virtual attendees during the International Gastric Cancer Educational Symposium on Thursday, June 17, 2021.

Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss results from the phase 1 study of MORF-057 following a presentation at the Congress of European Crohn’s and Colitis Organisation (ECCO) 2021 Virtual Congress.

SCYNEXIS, Inc., a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, announced grants of stock options to four new employees to purchase an aggregate of 18,100 shares of SCYNEXIS common stock at a per share exercise price of $7.36, the closing trading price on June 30, 2021.